AFAndria L. Ford

Andria L. Ford

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Andria L. Ford has a total of 38 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Crizanlizumab for retinal vasculopathy with cerebral leukoencephalopathy in a phase II clinical study

    by Wilson X. Wang, Dan Spiegelman, P. Kumar Rao, Rennie L. Rhee, Andria L. Ford, Jonathan J. Miner, Rajendra S. Apte


  • Open Access

    Crizanlizumab for retinal vasculopathy with cerebral leukoencephalopathy in a phase II clinical study

    by Wilson X. Wang, Dan Spiegelman, P. Kumar Rao, Andria L. Ford, Rajendra S. Apte

    Background: Retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations (RVCL-S) is a rare, autosomal dominant, universally fatal disease without effective treatment options. This study explores the safety and preliminary efficacy of crizanlizumab, a humanized monoclonal antibody against P-selectin approved for the prevention of sickle cell crises, in slowing retinal nonperfusion and preserving vision in patients with RVCL-S. METHODS: Eleven patients with RVCL-S with confirmed exonuclease 3 prime repair exonuclease 1 ( TREX1 ) mutations received monthly crizanlizumab infusions over 2 years. The study measured the nonperfusion index within 3 retinal zones and the total retina with fluorescein angiography, visual acuity, intraocular pressure (IOP), and optical coherence tomography central subfield thickness (CST) at baseline, 1 year, and 2 years. A mixed repeated-measures analysis was performed to assess the progression rates and changes from baseline. RESULTS: Eleven participants received crizanlizumab infusions. All of the participants tolerated crizanlizumab well, with 8 of 11 (72.7%) reporting mild adverse effects such as nausea, fatigue, and gastrointestinal symptoms. The change in total retinal nonperfusion was 7.22% [4.47, 9.97] in year 1 and –0.69% [–4.06, 2.68] in year 2 ( P < 0.001). In the mid periphery, the change in nonperfusion was 10.6% [5.1, 16.1] in year 1 and –0.68% [–3.98, 5.35] in year 2 ( P < 0.01), demonstrating a reduction in progression of nonperfusion in the second year of treatment. Visual acuity, IOP, and CST remained stable. CONCLUSION: Crizanlizumab has an acceptable safety profile. These results show promising potential for examining crizanlizumab in larger studies of RVCL-S and similar small-vessel diseases and for using the retina as a biomarker for systemic disease. Trial registration: ClinicalTrials.gov NCT04611880. FUNDING: The Clayco Foundation; DeNardo Education and Research Foundation Grant; Jeffrey T. Fort Innovation Fund; Siteman Retina Research Fund; unrestricted grant from Research to Prevent Blindness Inc.; National Heart,Lung, and Blood Institute (NHLBI), NIH (R01HL129241); National Institute of Neurological Disorders and Stroke (NINDS), NIH (RF1NS116565).


  • Abstract WP400: Magnetic Resonance-Derived Oxygen Extraction Fraction in White Matter Hyperintensities Compared to Normal Appearing White Matter

    by Peter Kang, Yasheng Chen, Andria L Ford, Hongyu An, Jin-Moo Lee

    Introduction: White matter hyperintensities (WMH), a common neuroradiological feature seen with aging, increases the risk of stroke, dementia, disability and mortality. The underlying pathophysiology leading to WMH is incompletely understood. Here, we examined the role of regional cerebral blood flow (CBF) and oxygen extraction fraction (OEF) in WMH. Methods: Subjects with WMH (n=9) and age-matched controls (n=9) were imaged in a 3T MRI Scanner. OEF was obtained using an asymmetric spin echo sequence while CBF was obtained with pseudo-continuous arterial spin labeling. WMH were graded according to Fazekas et al. For tissue-type quantification, CBF and OEF images were segmented to classify whole brain (WB), gray matter (GM), white matter (WM), white matter hyperintensities (WMH), and normal appearing white matter (NAWM). Results: CBF and OEF in WB, GM and WM did not differ between cohorts. However, differences emerged when comparing the WMH and NAWM segmented tissues. Specifically, CBF in WMH was less than half that seen in NAWM in the WMH group, and similarly lower than normal WM in controls. Moreover, OEF in WMH was higher compared to NAWM and WM in controls, but this did not reach statistical significance (Table). Conclusions: CBF and OEF did not differ between subjects with or without WMH. However, within the WMH group, regions of WMH had significantly lower but not absent CBF and trends towards higher OEF compared to NAWM and normal WM in controls. These data suggest that regions of WMH do not represent irreversibly infarcted tissue, but rather, may be viable tissue under chronic metabolic stress. Increased OEF in WMH may be a marker of salvageable brain tissue; However, additional work is needed to confirm these results.


  • Abstract TP210: Oxygen Extraction Fraction is Increased in the Borderzone Region of Healthy Young Adults

    by Andria L Ford, Kristin Guilliams, Melanie Fields, Dustin Ragan, Slim Fellah, Cihat Eldeniz, Michael Binkley, Yasheng Chen, Josh Shimony, Katie Vo, et al.

    Background: We have previously shown that the borderzone region demonstrates ischemic physiology, with low cerebral blood flow (CBF) and increased oxygen extraction fraction (OEF), in pediatric sickle cell anemia (SCA). This region is vulnerable in SCA as evidenced by increased infarct burden. Here we studied healthy adults to determine if borderzone physiology exists in the absence of apparent vascular disease. Methods: Healthy (N=17, 33 ± 9 yr) and SCA (N=13, 28 ± 7 yr) adults were recruited from a tertiary care SCA clinic. Individuals with vascular risk factors or chronic medical or neurological diseases were excluded. SCA subjects were excluded for stroke, vasculopathy, or transfusion therapy. Brain MRIs were prospectively obtained including: T1, FLAIR, dynamic susceptibility contrast (CBF), and asymmetric spin echo (OEF). Within each subject, 3 regions of low CBF were derived by normalizing CBF to its peak CBF. For gray matter (GM), regions were: < 25 th %, 25-50 th %, and 50-75 th % of mean thalamic CBF. For white matter (WM), regions were: < 25 th %, 25-35 th %, and 35-45 th % of mean GM CBF. Mean OEF across the 3 CBF regions were compared using Friedman test to account for repeated measures (Fig*). Results: Figure demonstrates the approximated borderzone with heatmaps (# of subjects with WM CBF < 25 th %) for healthy and SCA adults, alongside average OEF maps for each cohort. Both in healthy and SCA adults, GM and WM OEF were elevated in the region of lowest CBF. Furthermore, relative tissue volumes of CBF < 25 th % were higher in SCA than controls (GM: 16 vs 11%, pConclusion: We found ischemic physiology (low CBF / high OEF) in the borderzone of healthy adults. Additional stressors limiting cerebral oxygen delivery such as chronic anemia in SCA or carotid occlusion may lead to enlargement of the borderzone, further elevation of OEF, and a heightened vulnerability to infarction.

  • Streamlined Hyperacute Magnetic Resonance Imaging Protocol Identifies Tissue-Type Plasminogen Activator–Eligible Stroke Patients When Clinical Impression Is Stroke Mimic

    by Manu S. Goyal, Brian G. Hoff, Jennifer Williams, Naim Khoury, Rebecca Wiesehan, Laura Heitsch, Peter Panagos, Katie D. Vo, Tammie Benzinger, Colin P. Derdeyn, et al.

    Background and Purpose—: Stroke mimics (SM) challenge the initial assessment of patients presenting with possible acute ischemic stroke (AIS). When SM is considered likely, intravenous tissue-type plasminogen activator (tPA) may be withheld, risking an opportunity to treat AIS. Although computed tomography is routinely used for tPA decision making, magnetic resonance imaging (MRI) may diagnose AIS when SM is favored but not certain. We hypothesized that a hyperacute MRI (hMRI) protocol would identify tPA-eligible AIS patients among those initially favored to have SM. Methods—: A streamlined hMRI protocol was designed based on barriers to rapid patient transport, MRI acquisition, and post-MRI tPA delivery. Neurologists were trained to order hMRI when SM was favored and tPA was being withheld. The use of hMRI for tPA decision making, door-to-needle times, and outcomes were compared before hMRI implementation (pre-hMRI: August 1, 2011 to July 31, 2013) and after (post-hMRI, August 1, 2013, to January 15, 2015). Results—: Post hMRI, 57 patients with suspected SM underwent hMRI (median MRI-order-to-start time, 29 minutes), of whom, 11 (19%) were diagnosed with AIS and 7 (12%) received tPA. Pre-hMRI, no tPA-treated patients were screened with hMRI. Post hMRI, 7 of 106 (6.6%) tPA-treated patients underwent hMRI to aid in decision making because of suspected SM (0% versus 6.6%; P =0.001). To ensure standard care was maintained after implementing the hMRI protocol, pre- versus post-hMRI tPA-treated cohorts were compared and did not differ: door-to-needle time (39 versus 37 minutes; P =0.63), symptomatic hemorrhage rate (4.5% versus 1.9%; P =0.32), and favorable discharge location (85% versus 89%; P =0.37). Conclusions—: A streamlined hMRI protocol permitted tPA administration to a small, but significant, subset of AIS patients initially considered to have SM.


  • Accuracy of Emergency Medical Services–Reported Last Known Normal Times in Patients Suspected With Acute Stroke

    by David Curfman, Lisa Tabor Connor, Hawnwan Philip Moy, Laura Heitsch, Peter Panagos, Jin-Moo Lee, David K. Tan, Andria L. Ford

    Background and Purpose—: The last known normal (LKN) time is a critical determinant of IV tissue-type plasminogen activator (IV tPA) eligibility; however, the accuracy of emergency medical services (EMS)-reported LKN times is unknown. We determined the congruence between neurologist-determined and EMS-reported LKN times and identified predictors of incongruent LKN times. Methods—: We prospectively collected EMS-reported LKN times for patients brought into the emergency department with suspected acute stroke and calculated the absolute difference between the neurologist-determined and EMS-reported LKN times (|ΔLKN|). We determined the rate of inappropriate IV tPA use if EMS-reported times had been used in place of neurologist-determined times. Univariate and multivariable linear regression assessed for any predictors of prolonged |ΔLKN|. Results—: Of 251 patients, mean and median |ΔLKN| were 28 and 0 minutes, respectively. |ΔLKN| was P P =0.019) were independent predictors of prolonged |ΔLKN|. Conclusions—: EMS-reported LKN times were largely congruent with neurologist-determined times. Focused EMS training regarding wake-up stroke symptoms may further improve accuracy.


  • Acute Ischemic Stroke: Evidence-Based Neuroimaging

    by Andria L. Ford, Jin-Moo Lee, Weili Lin, Katie D. Vo

  • Patent Foramen Ovale and Stroke: Should PFOs Be Closed in Otherwise Cryptogenic Stroke?

    by David A. Carpenter, Andria L. Ford, Jin-Moo Lee

    Since initial reports of its association with ischemic stroke appeared in 1988, there has been continued controversy regarding the existence and strength of the association between patent foramen ovale (PFO) and ischemic stroke. Many case-control studies have reported an association between incident cryptogenic ischemic stroke and PFO, yet population-based studies have failed to confirm this association. Studies of the risk of recurrent stroke in patients with cryptogenic stroke with or without PFO have not shown an increased risk of recurrent stroke in patients with PFO. Meanwhile, use of devices to close PFOs and atrial septal defects percutaneously has increased dramatically since their introduction. Completion of the randomized clinical trials of PFO closure currently in progress is vital to determine if the benefits of PFO closure in cryptogenic stroke outweigh its risks.